3/3
12:40 pm
tem
Tempus AI (TEM) had its price target lowered by Morgan Stanley from $85.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
Tempus AI (TEM) had its price target lowered by Morgan Stanley from $85.00 to $70.00. They now have an "overweight" rating on the stock.
3/3
08:30 am
tem
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
Medium
Report
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
2/28
01:30 am
tem
Low
Report
2/26
08:30 am
tem
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
Medium
Report
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
2/25
04:43 pm
tem
Tempus AI: No AI Interruption Detected [Seeking Alpha]
Medium
Report
Tempus AI: No AI Interruption Detected [Seeking Alpha]
2/25
01:11 pm
tem
Tempus AI (TEM) was given a new $60.00 price target by Stifel Nicolaus.
Low
Report
Tempus AI (TEM) was given a new $60.00 price target by Stifel Nicolaus.
2/25
12:58 pm
tem
Tempus AI (TEM) had its price target lowered by JPMorgan Chase & Co. from $80.00 to $60.00. They now have a "neutral" rating on the stock.
Low
Report
Tempus AI (TEM) had its price target lowered by JPMorgan Chase & Co. from $80.00 to $60.00. They now have a "neutral" rating on the stock.
2/25
11:32 am
tem
Tempus AI (TEM) had its price target lowered by Needham & Company LLC from $100.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Tempus AI (TEM) had its price target lowered by Needham & Company LLC from $100.00 to $75.00. They now have a "buy" rating on the stock.
2/25
08:03 am
tem
Tempus AI (TEM) had its price target lowered by BTIG Research from $105.00 to $90.00. They now have a "buy" rating on the stock.
Medium
Report
Tempus AI (TEM) had its price target lowered by BTIG Research from $105.00 to $90.00. They now have a "buy" rating on the stock.
2/25
12:27 am
tem
Tempus AI Inc (TEM) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
Tempus AI Inc (TEM) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... [Yahoo! Finance]
2/24
04:01 pm
tem
Tempus Reports Fourth Quarter and Full Year 2025 Results
Low
Report
Tempus Reports Fourth Quarter and Full Year 2025 Results
2/20
07:28 am
tem
Tempus AI (NASDAQ:TEM) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Medium
Report
Tempus AI (NASDAQ:TEM) was upgraded by analysts at Mizuho to a "strong-buy" rating.
2/19
07:07 am
tem
Tempus AI (NASDAQ:TEM) was given a new $100.00 price target on by analysts at Mizuho.
Medium
Report
Tempus AI (NASDAQ:TEM) was given a new $100.00 price target on by analysts at Mizuho.
2/18
11:45 am
tem
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
Low
Report
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
2/18
08:30 am
tem
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
Medium
Report
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
2/18
06:58 am
tem
Tempus AI (NASDAQ:TEM) was upgraded by analysts at Robert W. Baird to a "strong-buy" rating.
Medium
Report
Tempus AI (NASDAQ:TEM) was upgraded by analysts at Robert W. Baird to a "strong-buy" rating.
2/17
07:17 am
tem
Tempus AI (NASDAQ:TEM) was given a new $59.00 price target on by analysts at Robert W. Baird.
Low
Report
Tempus AI (NASDAQ:TEM) was given a new $59.00 price target on by analysts at Robert W. Baird.
2/12
04:05 pm
tem
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
Medium
Report
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
2/12
04:05 pm
tem
Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
Low
Report
Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
2/10
08:30 am
tem
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
Low
Report
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
2/4
10:36 pm
tem
Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]
Low
Report
Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]
2/4
07:00 am
tem
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
Medium
Report
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
2/2
07:13 am
tem
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield [Yahoo! Finance]
Low
Report
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield [Yahoo! Finance]
2/2
07:00 am
tem
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield
Low
Report
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield
2/1
07:03 pm
tem
Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones [Yahoo! Finance]
Low
Report
Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones [Yahoo! Finance]